Early growth response-1 (EGR1) is a transcription factor correlated with prostate cancer (PC) progression in a variety of contexts. For example, EGR1 levels increase in response to suppressed androgen receptor signaling or loss of the tumor suppressor, PTEN. EGR1 has been shown to regulate genes influencing proliferation, apoptosis, immune cell activation, and matrix degradation, among others. Despite this, the impact of EGR1 on PC metastatic colonization is unclear. We demonstrate using a PC model (DU145/RasB1) of bone and brain metastasis that EGR1 expression regulates angiogenic and osteoclastogenic properties of metastases. We have shown previously that FN14 (TNFRSF12A) and downstream NF-κB signaling is required for metastasis in this model. Here we demonstrate that FN14 ligation also leads to NF-κB-independent, MEK-dependent EGR1 expression. EGR1-depletion in DU145/RasB1 cells reduced both the number and size of metastases but did not affect primary tumor growth. Decreased EGR1 expression led to reduced blood vessel density in brain and bone metastases as well as decreased osteolytic bone lesion area and reduced numbers of osteoclasts at the bone-tumor interface. TWEAK (TNFSF12) induced several EGR1-dependent angiogenic and osteoclastogenic factors (e.g., PDGFA, TGFB1, SPP1, IL6, IL8, and TGFA, among others). Consistent with this, in clinical samples of PC, the level of several genes encoding angiogenic/osteoclastogenic pathway effectors correlated with EGR1 levels. Thus, we show here that EGR1 has a direct effect on prostate cancer metastases. EGR1 regulates angiogenic and osteoclastogenic factors, informing the underlying signaling networks that impact autonomous and microenvironmental mechanisms of cancer metastases.
Introduction
Early growth response-1 (EGR1) is an early response gene that is involved in growth, differentiation, apoptosis, neurite outgrowth, and wound healing. As a transcription factor, EGR1 has a highly conserved DNA-binding domain composed of three zinc fingers that bind to the GC-rich consensus sequence GCG (G/T) GGGCG. EGR1 is induced by cytokines, growth factors, and stress signals such as radiation, injury, or mechanical stress [1] . Although EGR1 has significant tumor suppressor properties in many types of cancer [2] [3] [4] , emerging evidence indicates that EGR1 is a tumor promoter in prostate cancer (PC). It has been reported that silencing EGR1 impairs the progression from prostatic intraepithelial neoplasia to adenocarcinoma in the cryptdin-2-T-antigen and transgenic adenocarcinoma of the mouse prostate (TRAMP) model [5] . In addition, using in situ hybridization to analyze 96 prostate specimens, Eid et al. demonstrated that quantified EGR1 mRNA levels positively correlated with PC Gleason grade [6] . Nevertheless, a role for EGR1 in PC metastasis has not been established.
Elevated EGR1 levels are associated with PC progression. For example, EGR1 expression and activity increase following experimental Pten loss [7] . PTEN deletion occurs in about 20% of primary and 40% of metastatic clinical PCs [8] . In addition, EGR1 expression is increased with castration [7] , and overexpressing EGR1 promotes LNCaP tumor growth in castrated nude mice [9] . EGR1 coimmunoprecipitates with AR and promotes AR-dependent transcription of PSA in PC cells [10] , suggesting that EGR1 acts through an AR-dependent mechanism in promoting castration resistance. Importantly, however, EGR1 regulates various AR independent properties associated with advanced PC as well. Forced EGR1 expression in AR positive and negative PC cell lines increased various proteins that are associated with invasive activity (hPAR, HYAL-1, HPSE, and MMP9) [1, 11] . Despite these advances, the mechanistic contribution of EGR1 to PC metastasis is poorly defined.
Metastasis is the predominant cause of mortality in PC [12] . Bone metastasis occur in 90% of metastatic PC patients and can lead to severe pain, pathological fracture, nerve compression, and hypercalcemia [13] . PC brain metastasis is rare and often represents an end-stage lethal progression [14] [15] [16] [17] . We previously characterized a PC xenograft model that develops bone and brain metastasis dependent upon Ras pathway activation in the DU145/ RasB1 cell line [18] . Various genetically engineered mouse models, additional human PC cell line models, and genetic and histological analyses of primary clinical tissues have contributed to the conclusion that Ras pathway activation is associated with PC metastasis [19] [20] [21] [22] [23] [24] .
In the DU145/RasB1 model, we previously identified FN14 (TNFRSF12A) as an overexpressed receptor that is necessary for efficient metastatic colonization [25] . FN14 binds the TNF family ligand, TWEAK, one consequence of which is initiation of NF-κB signaling. The downstream targets of the TWEAK-FN14 pathway that contribute to metastatic properties, however, have yet to be characterized in PC cells. In this study, we identify EGR1 as a major downstream effector of the TWEAK-FN14 pathway and demonstrate that EGR1 promotes PC bone and brain metastasis. We show that EGR1 regulates angiogenic and osteoclastogenic factors in PC, providing novel mechanistic insights into the role of EGR1 in PC metastasis.
Results

EGR1 expression is dysregulated in advanced PC
To investigate the downstream targets of the TWEAK-FN14 pathway, we analyzed the gene expression profile of highly metastatic DU145/RasB1 (B1) cells before and after treatment with TWEAK. Microarray analysis revealed a small number of differentially expressed genes, including early growth response gene family (EGR1-4) transcription factors (Fig. 1a) . EGR1, the most extensively studied of the family members, was the most highly expressed (Fig. 1b) . Validation PCR analysis demonstrated that EGR1 as well as the NF-κB targets, IL-8 and IκBα, were stimulated by TWEAK-FN14 pathway activation (Fig. 1b) . To validate the microarray result at the protein level, DU145 B1 cells were treated with TWEAK for various times. Nuclear EGR1 protein levels transiently increased between 15 and 120 min after TWEAK addition (Fig. 1c) . Depletion of FN14 with shRNA blocked the EGR1 nuclear protein levels stimulated by TWEAK treatment (Fig. 1c) , demonstrating that EGR1 induction was a specific consequence of FN14 receptor engagement.
To determine whether EGR1 may play a role in clinical PC progression, we analyzed the gene expression of EGR1 in samples of primary PC [8] with Gleason ≥ 7 as well as in a metastatic castration resistant PC (mCRPC) cohort composed of adenocarcinoma and enriched for neuroendocrine histologies [26] . The results indicated that EGR1 expression in primary PC was relatively uniform with only 6% demonstrating an mRNA expression z-score ≥ 2. By contrast, mCRPC patient samples represented a broad distribution with 40% having z-scores ≥ 2 (Fig. 1d) . Average EGR1 expression between adenocarcinoma (mCRPCadeno) and neuroendocrine (mCRPC-NE) samples showed no significant difference, suggesting that EGR1 levels were not associated with a specific pathological phenotype in these patient samples (Fig. 1e) . Collectively, these data indicate that EGR1 is increased in response to TWEAK-FN14 pathway activation in DU145/RasB1 cells and that EGR1 is elevated in a subset of clinical mCRPC samples.
The TWEAK-FN14 pathway induces EGR1 expression via MEK/ERK signaling Previously, we demonstrate that the NF-κB p50/p65 pathway is a downstream mediator of TWEAK-FN14 in DU145 B1 cells [25] . To determine whether EGR1 is downstream of the NF-κB pathway, we used DU145 B1/ IκBαSR cells, a cell line expressing a doxycycline-inducible, degradationresistant IκBα super repressor (IκBαSR) that blocks both canonical and noncanonical NF-κB pathway by preventing the nuclear translocation of RELA (p65) and indirectly inhibiting synthesis of the NFKB2 (p52) precursor, p100 [27] . Prior doxycycline induction of IκBαSR abolished TWEAK-stimulated nuclear translocation of p65 and p52, whereas EGR1 nuclear protein was still increased by TWEAK treatment (Fig. 2a) . This result suggested that NF-κB is not upstream of EGR1. To investigate whether EGR1 is required for activation of the NF-κB pathway, we used lentivirus-encoded shRNAs to knock down EGR1 in DU145/RasB1 cells. The data demonstrated that despite decreased EGR1 levels in the nucleus, both p65 and p52 nuclear protein translocation were still stimulated by TWEAK treatment in DU145 B1/EGR1shRNA cells (Fig.  2b) , indicating that EGR1 is not upstream of NF-κB. Decreased levels of EGR1 did not appear to be compensated for by EGR2, EGR3, or EGR4 ( Supplementary Fig.  1 ). These data suggest that EGR1 and NF-κB are independent pathways stimulated by TWEAK engagement of FN14.
It has been reported that MEK/ERK signaling is stimulated downstream of FN14 ligation [28, 29] . Therefore, DU145 B1 cells were stimulated by TWEAK with or without the MEK1/2 inhibitor AZD8330, and nuclear EGR1 levels were determined. As shown in Fig. 2c , prior treatment with AZD8330 blocked TWEAK-stimulated ERK1/2 phosphorylation and reduced EGR1 nuclear protein levels (Fig. 2c) , showing that EGR1 induction requires MEK/ERK signaling.
EGR1 is essential to the invasiveness of DU145/ RasB1
To characterize the biological function of EGR1 in DU145 B1 cells, we first determined the effect of EGR1 depletion on in vitro cell proliferation and in vivo tumorigenesis using Fig. 1 TWEAK-FN14 pathway activation stimulates EGR1, and dysregulated EGR1 expression is observed in prostate cancer metastasis. a Microarray analysis of EGR1-4 in response to TWEAK (25 ng/ml) treatment for 60 min. b qPCR analysis of EGR1, IL8, and NFKBIA (IκBα) in DU145/RasB1 prostate cancer cell line treated with TWEAK (25 ng/ml) for 1 h. ***P < 0.001, ****P < 0.0001. c Western blot analysis of FN14, EGR1, NFKB2 (p52), and RELA (p65) in DU145/RasB1/EV and DU145/RasB1/FN14 shRNA. Cells were treated with TWEAK for various times. FN14 was detected in the cytoplasmic fraction. p65, p52, and EGR1 were detected in the nuclear fraction. α-tubulin was the loading control for cytoplasmic extracts. LaminB1 was the loading control for nuclear extracts. d Percentage of mCRPC and primary prostate cancer patient samples with EGR1 expression z-score ≥ 2. The numbers on top of each bar indicate the ratio of patient samples with EGR1 expression (z-score ≥ 2) over total samples in mCRPC or primary prostate cancer cohorts. The numbers inside the bar indicated the ratio of patient samples with EGR1 expression (z-score ≥ 2) over total mCRPC-NE or mCRPCadeno samples. e EGR1 mRNA expression in NEPC WCM 2016 mCRPC-adeno (n = 31) or mCRPC-NE (n = 15) patient samples with EGR1 expression z-score ≥ 2 in mCRPC cohort ** (Fig. 2b) . Our results revealed that decreased levels of EGR1 slightly reduced the growth rate of DU145 B1 cells but had no effect upon tumorigenesis (Fig. 2d, e) .
To assess the role of EGR1 in PC invasiveness, we performed invasion assays by seeding DU145 B1/EV and DU145 B1/EGR1shRNA cells on Matrigel-coated Transwell dishes. EGR1 depletion significantly reduced the number of invading DU145 B1 cells in vitro after 12 h (Fig.  2f) , suggesting that EGR1 influences the invasiveness of PC cells. Adhesion and migration are two components that contribute to tumor invasiveness. However, as shown in Supplementary Fig. 2A -C, decreased invasiveness cannot be accounted for by reduced adhesion to fibronectin, collagen I, collagen IV, or fibrin or by decreased migration ability.
EGR1 promotes experimental PC bone and brain metastasis DU145 B1/EV or DU145 B1/EGR1shRNA cell lines (shRNA11 and shRNA51) (Fig. 2b) were used to investigate the influence of EGR1 levels on metastatic capability. Following inoculation to the left cardiac ventricle, mice bearing either of the DU145 B1/EGR1shRNA cells developed significantly less bone (Fig. 3a, b ) and brain metastases (Fig. 3a , c) compared with mice bearing DU145 B1/ EV cells, as measured by total bioluminescent imaging (BLI) signal. The reduced luminescence in EGR1 depleted lines was a consequence of reduced numbers of bone ( Fig.  3d ) and brain metastatic foci (Fig. 3e ) as well as decreased tumor sizes. These results suggested that EGR1 contributes to the metastatic colonization of this aggressive PC model.
In addition, mice inoculated with DU145 B1/EGR1shRNA cells demonstrated less metastasis-associated morbidity as they maintained their body weight, while mice bearing DU145 B1/EV cells did not (Fig. 3f) .
We previously demonstrated that NF-κB signaling is required for metastasis in the DU145 B1 xenograft model [25] . This study indicated that EGR1 was necessary for PCa metastasis ( Fig. 3) and that the TWEAK-FN14 pathway induced EGR1 expression in a MEK/ERK-dependent, NF-κB-independent fashion (Fig. 2a-c) , leading to the question of whether NF-κB signaling and EGR1 additively promote PC metastasis. To address this question in the DU145 B1model, we inhibited each pathway singly or together and measured bone and brain metastasis. However, since the tumor burden was so significantly reduced by blocking the NF-kB pathway alone, further blockade of EGR1 showed no additional reduction in tumor burden or the kinetics of metastasis development ( Supplementary Fig. 3A-D) .
We also asked whether EGR1 expression contributes to bone metastasis in other models. Currently, there are relatively few bone metastasis models. Although PC-derived PC3 cells form bone metastasis, PC3 cells do not express detectable EGR1 protein ( Supplementary Fig. 4A ). The MDA-MB-231 breast cancer cell line expressed EGR1 in a TWEAK-independent fashion at five-to tenfold lower levels than DU145 B1 cells ( Supplementary Fig. 4A ). We 
EGR1 stimulates angiogenesis in bone and brain metastases of DU145/RasB1
Our previous work characterized DU145 B1 cells as highly angiogenic [34] . Since EGR1 has been increasingly recognized as a regulator of angiogenesis, we analyzed the blood vessel density, using the CD34 endothelial marker, within bone and brain metastatic lesions of DU145 B1/EV and DU145 B1/EGR1shRNA derived tumors. Interestingly, for both bone and brain metastases, depleting a Western blot analysis of IκBα, p65, p52, and EGR1 in DU145/ RasB1/TRE3G-IκBαSR cells. Cells were treated with TWEAK (25 ng/ ml) for various times. IκBα was detected in the cytoplasmic fraction; p65, p52, and EGR1 were detected in the nuclear fraction. b Western blot analysis of nuclear EGR1, p52, and p65 in DU145/RasB1/EV, DU145/RasB1/EGR1 shRNA11, and DU145/RasB1/EGR1 shRNA51. Cells were treated with TWEAK (25 ng/ml) for various times. c Western blot analysis of EGR1, p65, p52, ERK2, and p-ERK1/2 in DU145/RasB1. Cells were incubated with MEK1/2 inhibitor AZD8330 (1 µM) for 2 h before TWEAK treatment. ERK2 and p-ERK1/2 were detected in the cytoplasmic fraction. p65, p52, and EGR1 were detected in the nuclear fraction. d Proliferation rate of DU145 B1/EV, DU145 B1/EGR1shRNA11, and DU145 B1/ EGR1shRNA51 in culture. e Volumes of DU145 B1/EV or DU145 B1/EGR1shRNA11 tumors over time. f Top panel: representative images of HEMA3-stained DU145 B1/EV and DU145 B1/ EGR1shRNA11 cells following invasion for 12 h. Bottom panel: quantification of invaded cells in transwell assay. **P < 0.01 EGR1 significantly reduced the relative blood vessel area in tumors ( Fig. 4a-d) . Because angiogenesis increases with tumor size and because EGR1-depleted metastases were on average smaller than DU145 B1/EV metastases, we determined the blood vessel density relative to tumor area across a range of metastases collected at various time points. Our 
EGR1 stimulates osteoclastogenesis in bone metastases
To further characterize the phenotype of bone metastasis, we analyzed x-ray images of mice bearing DU145 B1/EV and DU145 B1/EGR1shRNA tumors, which revealed mainly osteolytic metastases with an osteoblastic component (Fig. 3a) . To determine the role of EGR1 in the development of DU145 B1-mediated osteolysis, we quantified the osteolytic area on radiographic imaging of long bones in DU145 B1/EV and DU145 B1/EGR1shRNA bearing mice. The data demonstrated that depleting EGR1 significantly decreased the osteolytic lesion area (Fig. 5a, b) . Consistent with this, histological analysis indicated that EGR1 knockdown significantly reduced the number of tartrate-resistant acid phosphatase-positive (TRAP + ) osteoclasts on bone-tumor interface (Fig. 5a, c) .
EGR1 regulates angiogenic and osteoclastogenic factors expression in PC
To begin addressing the relationship of the model described here to clinical PC, we asked whether EGR1 levels are correlated with angiogenic and/or osteoclastogenic factor RNA levels in clinical PC data sets. For primary PC samples [8] , we limited our analysis to Gleason score ≥ 7 samples, and the 25% of patient samples (n = 113) with the highest EGR1 expression were compared to the 25% of patient samples (n = 113) with the lowest EGR1 expression levels (Fig. 6a) . Gene set enrichment analysis (GSEA) revealed that the hallmark angiogenesis gene set was significantly enriched in the top quartile as compared to the bottom quartile of patient samples defined by EGR1 expression (Fig. 6b) . Similarly, EGR1 levels were correlated with the angiogenic signature in a phenotypically diverse data set of CRPC-adeno and CRPC-NE metastases (Fig. 6c ) [26] . The distribution of gene expression making up the angiogenic signature are shown for CRPC samples in Supplementary Fig. 5 . A similar analysis was performed for osteoclastogenic genes. EGR1 clearly clustered with global osteoclastogenic signature genes ( Supplementary Fig. 6 ) comparing the top and bottom EGR1 expression quartiles for primary PC with Gleason scores ≥ 7. In addition, across all samples of Gleason score ≥ 7, EGR1 positively correlated with nine osteoclastogenic factors, including LIF, IL1B, OSM, CSF3, CCL2, TNF, VCAM1, CSF1, and PTHLH RNA levels (Supplementary Table 1 ). EGR1 is induced by TWEAK in DU145 B1 cells. To determine whether TWEAK stimulated proangiogenic and/ or osteoclastogenic factors via an EGR1-dependent mechanism, we treated DU145 B1/EV and DU145 B1/ EGR1shRNA cells with TWEAK and performed qRT-PCR to detect gene expression of 47 proangiogenic/osteoclastogenic factors (Supplementary Table 2 ) [35, 36] . TWEAK treatment increased gene expression for 12 proangiogenic factors in DU145 B1/EV cells, including VEGFA, PDGFA, TGFB1, HIF1A, FGF2, SPP1, IL6, TGFA, ITGAV, EFNA1, IL8, and CXCL1 (Fig. 6d) . In addition, TWEAK treatment increased gene expression for the osteoclastogenic factors, CSF2 and TNFα (Fig. 6d) . Interestingly, some angiogenic factors such as CXCL1, IL6, TGFB1, and SPP1 have been found to also influence osteoclast and/or osteoblast development and function [37] [38] [39] [40] . Depletion of EGR1 inhibited induction of these genes found to be regulated by TWEAK and returned many but not all of the affected RNA levels to baseline (Fig. 6d) . IL8, a known NF-κB target, was only partially inhibited by EGR1 depletion, suggesting additive regulation by EGR1 and NF-κB. These data suggested that TWEAK stimulation of proangiogenic factors in the DU145 B1 model is mediated in large part by EGR1. We asked whether EGR1-regulated, soluble osteoclastogenic factors could be functionally detected in DU145 B1 cell culture supernatants. We performed an in vitro osteoclastogenesis assay that measured osteoclast maturation of a mouse monocyte cell line. RAW264.7 were primed with RANKL for 2 days, cultured with conditioned media (CM) from DU145 B1/EV or either of DU145 B1/ EGR1shRNA cells for additional 2 days followed by TRAP staining (Supplementary Fig. 7A ). As shown in Supplementary Fig. 7B & C, CM from DU145 B1/EV induced significantly more TRAP + osteoclasts compared with CM Fig. 3 Blocking EGR1 expression inhibits prostate cancer metastases to bone and brain. a Representative bioluminescent and x-ray images from mice bearing DU145 B1/EV or DU145 B1/EGR1shRNA metastasis. Arrows indicate osteolytic lesions. b Quantification of bone metastasis burden shown as mean photonflux. EV and shRNA11: n = 10 mice; shRNA51: n = 9 mice; **P < 0.01; ***P < 0.001; the median value is indicated by a horizontal line within the box. c Quantification of brain metastasis burden shown as mean photonflux. EV and shRNA11: n = 10 mice per group; shRNA51: n = 9 mice; ***P < 0.001; the median value is indicated by a horizontal line within the box. d Number of bone metastatic foci per mouse from each experimental group determined using bioluminescent imaging. e Number of brain metastatic foci per mouse from each experimental group determined using bioluminescent imaging. f Average body weight of mice bearing DU145 B1/EV or DU145 B1/EGR1shRNA tumors over time following inoculation (EV, n = 10; shRNA11, n = 10; shRNA51, n = 9). *P < 0.05 vs EV; ****P ≤ 0.0001 vs EV from DU145 B1/EGR1shRNA cells. These results demonstrate that EGR1 plays a role in the production of soluble osteoclastogenic factors.
Finally, we determined for those angiogenic/osteoclastogenic genes regulated in the DU145 B1 cells by EGR1 [26] whether evidence exists for similar regulation in 
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Brain metastasis (Fig. 6f) . Notably, EGR1 did not correlate with FN14 levels, however. This may be due to the fact that EGR1 is regulated by various upstream pathways (see 'Discussion'). In addition, we have observed a lack of correlation between FN14 RNA and protein in some model systems, suggesting that FN14 RNA cannot be used in correlation analyses.
Discussion
Using an experimental metastasis model and correlative analyses of clinical samples, we show that EGR1 contributes to PC metastasis, probably as a result of regulating a variety of angiogenic/osteoclastogenic/immune modulatory factors. EGR1 is necessary for efficient bone and brain metastasis in the AR-independent, DU145/RasB1 model of experimental PC metastasis. EGR1 has been hypothesized to play various roles in PC pathogenesis, including castration resistance, extracellular matrix degradation, apoptosis, and cancer progression [1, 41] . The data presented here directly address a role for EGR1 in PC metastasis. Importantly, for experimental metastasis, EGR1 depletion had relatively little effect upon in vitro growth or tumorigenesis, but instead, decreased metastatic efficiency and reduced growth in those metastases that did arise (Figs. 2 and 3 ). EGR1 depleted metastases demonstrated less angiogenesis in the brain and bone and less osteoclast activity in the bone, characteristics that anticipate reduced growth (Figs. 4  and 5 ). The analysis of large primary and metastatic clinical sample data sets was consistent with highly deregulated EGR1 expression in a large proportion of metastatic samples (Fig. 6) . The role of EGR1 as a transcriptional regulator of angiogenic factors has been increasingly recognized. For example, EGR1 has recently been shown to be a key target of the miR-192 regulatory network that is predictive of poor clinical outcome in several cancer types as a result of modulating the angiogenic switch [36] . Interestingly, there are several EGR1-regulated genes encoding secreted factors, including TGFβ, IL-8, IL-6, SPP1, and CXCL-1, that influence osteoclast differentiation in addition to angiogenesis [37] [38] [39] [40] . Consistent with this, EGR1 expression influenced the extent of soluble osteoclastogenic activity produced in cell supernatants of DU145 B1 cells (Supplementary Fig. 7 ). In agreement with the experimental data presented here, EGR1 expressing clinical PC samples were enriched for expression of global angiogenic and osteoclastogenic signatures (Fig. 6b , c, Supplementary Figs. 2 and 3 ). In addition, experimentally validated individual EGR1-regulated angiogenic (PDGFA) and osteoclastogenic (CSF2, TNF) genes as well as those affecting both of these processes (IL6, IL8, and CXCL1) demonstrated a significant correlation with EGR1 levels in clinical data sets. Our observations in DU145 B1 cells are corroborated by reports using other tissue types that demonstrate EGR1 binding to the FGF2 [42] , PDGFA [43] , TNF [44] , IL8 [45] , and TGFB1 [46] promoters. Although EGR1/2 have been shown to be involved in osteogenic differentiation [47] , an involvement in the development of bone metastasis has not been widely appreciated. There is a known requirement for osteoclastogenesis, even in the formation of osteoblastic metastasis [48] .
We show here, consistent with other reports, that EGR1 induction was dependent upon MEK-ERK pathway signaling [1] . The RAS/RAF/ERK pathway is dysregulated in 43% of primary PC and >90% of PC metastasis when considering combined copy number alterations, transcriptomic and mutational data [24] . Similarly, RAF and ERK activation, as determined by tissue staining, occur at high frequency and have been observed to increase with PC progression [20, 49] . We show here that TWEAK binding to the FN14 receptor in DU145/Ras cells initiates MEKdependent, NF-kB-independent EGR1 expression. EGR1 is an early response gene regulated by a variety of soluble factors and stress stimuli. For example, EGR1 is induced in DU145 cells by diverse stimuli, including CXCL5, hypoxia, and radiation [50] [51] [52] . Thus, it is likely that elevated EGR1 expression in metastatic PC clinical samples may be secondary to a variety of mutational or microenvironmental effects, including but not limited to FN14 engagement. Taken together, our data identify a MEK/ERK-EGR1 pathway, an important physiological consequence of which is increased angiogenesis and osteoclastogenesis contributing to PC metastasis (Fig. 7) . These data provide a rationale for the development of EGR1-targeted therapies and suggest consideration of MEK-dependent EGR1 inhibition as one component of a therapeutic approach to treating advanced metastatic PC.
Materials and methods
shRNA-mediated gene silencing in DU145/RasB1 and MDA-MB-231 cells DU145, MDA-MB-231, and PC3 cells were obtained from ATCC. All genetically engineered cell lines were established using lentiviral vectors following standard procedures [18] . DU145/RasB1 cells infected with a pFUGW lentiviral expression clone containing mutant IkBα super repressor (IkBαSR; IkBaS32A, S36A) under the control of the TRE3G promoter with an IRES-mCherry reporter have been described [25] . IkBαSR expression was induced with 1 mg/ml doxycycline. EGR1 gene expression was silenced with EGR1 shRNAs in the pGIPZ lentiviral vector, designed by the RNAi Consortium (Open Biosystems) and targeting the following sequences: 5′-TATCCCATGGGCAATAAAG-3′ (shRNA 11), 5′-ACATTCTGGAGAACCGAAG-3′ (shRNA28), 5′-ATACACCACATATCCCATG-3′ (shRNA51), 5′-TTGTC TGCTTTCTTGTCCT-3′ (shRNA80), and 5′-TAGGGTAG TTGTCCATGGT-3′ (shRNA83).
Animal experiments
Six-to eight-week-old male athymic nude mice (Ncr nu/nu) and NOD scid gamma were obtained from the National Cancer Institute, Frederick, MD. Animal care was provided in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals. Prior to injection, cells were harvested from subconfluent cell culture with trypsin, resuspended in RPMI 1640 with10% fetal bovine serum, rotated at room temperature for 1 h, spun down, and washed in PBS. Cells were counted and diluted to the appropriate concentration.
Systemic tumor metastasis
A total of 10 5 tumor cells in 0.1 ml of PBS were inoculated into the left cardiac ventricles of male nude mice or NOD scid gamma after anesthetizing them with 1.5% isoflurane. Each experimental group included a minimum of five mice. Mice were allocated to each group randomly. Mice were euthanized after weight loss of >10% body weight or after demonstrating signs of paralysis. Four long bones (two front limbs with scapulae and two hind limbs), spines, and brain were collected and fixed in 10% paraformaldehyde for histological analysis (Histoserv, Inc., Germantown, MD, USA). 
Genetic analysis of PC patient samples
To investigate whether EGR1 clusters with global gene expression of proangiogenic factors or osteoclastogenic factors in PC, we obtained data for the TCGA primary PC [8] and the NEPC WCM 2016 mCRPC [26] cohorts and generated heatmaps using the HeatMapImage tool (https:// software.broadinstitute.org/cancer/software/genepattern/). To analyze the correlation of EGR1 and proangiogenic or osteoclastogenic genes in PC, we retrieved data for primary PC [8] and mCRPC [26] cohorts from cBioPortal. The mRNA data were log2 transformed. The correlation between EGR1 and proangiogenic or osteoclastogenic genes was then analyzed by Pearson correlation test and plotted using GraphPad Prism 7.
GSEA analysis
For the GSEA, GSEA software was downloaded from Broad Institute. The 25% of samples (n = 113) with the highest EGR1 expression and the 25% of samples (n = 113) with the lowest EGR1 expression from the TCGA primary PC cohort [8] were assigned to two groups. Patient samples with the highest (n = 10) or lowest (n = 10) EGR1 expression in the NEPC WCM 2016 mCRPC cohort [26] were assigned to two groups. The number of permutations was set to 1000, and the permutation type was set to "phenotype." A normalized enrichment score and false discovery rate were calculated by the program.
Microarray
DU145/RasB1 cells were treated with TWEAK (25 ng/ml, R&D Systems, Minneapolis, MN, USA) for 60 min. Total RNA was extracted using mirVana Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA). After TWEAK treatment, samples were validated for increased expression levels of known NFκB target genes, IL8 and IκBα, and submitted for microarray analysis. Microarray analysis was performed with Affymetrix Human Genome U133A 2.0 Array. Fold changes in gene expression were determined by ANOVA using Partek Genomics Suite (Partek, Chesterfield, MO, USA).
Real-time PCR
Quantative PCR was performed using SYBR Green Mastermix (Roche, Basel, Switzerland) and the Stepone Plus RT PCR System (Applied Biosystems, Foster City, CA, USA). All reactions were run in triplicate using primers listed in Supplementary Table 3 . Values were normalized to GAPDH unless otherwise stated. Each experiment was repeated three times.
Western blotting
Nuclear and cytoplasmic protein fractions were separated by using NE-PER TM Nuclear and Cytoplasmic Extraction 
Invasion assay
Invasion chambers were prepared by coating 8 μM pore, 24-well format membranes (BD Biosciences, San Jose, CA, USA) with 100 μl (0.5 mg/ml) Matrigel (Corning Inc.) per well and incubating them overnight at room temperature. Cells were harvested with trypsin, allowed to recover for 1 h with rocking in 10% FCS, washed in PBS, and resuspended to 10 6 cells/ml. Two hundred microliters of cells were placed into the upper chamber while 500 μl RPMI 1640 were placed into the bottom. Cells were incubated for 12 h at 37°C/5% CO2. Invasion was assayed as previously described [53] . Each experiment was repeated three times.
Histology, immunohistochemistry (IHC), and histomorphometric analysis
Long bones were decalcified in 10% EDTA and embedded in paraffin, and sections were stained with hematoxylin and eosin (H&E) and orange G. All mouse brains were stained with H&E. For IHC, slides were autoclaved at 121°C for 10 min in target retrieval solution (DAKO, Santa Clara, CA, USA), followed by CD34 antibody (1:2000, Abcam). TRAP staining was performed as previously described [18] . For histomorphometric analysis, bright-field microscopic images were acquired randomly with a AxioScan Z1 microscope using a 20× /NA 0.8 plan apochromat objective (Zeiss, Oberkochen, Germany). CD34-stained blood vessel areas were quantified using ImageJ (NIH, Bethesda, MD, USA) as described previously [34] . TRAP + osteoclast number per millimeter of tumor/bone interface was counted at ×20 magnification as described previously [34, 54] . All analyses were performed blindly.
In vitro growth determinations
Cells were seeded in six replicates in 96-well plates at densities of 2 × 10 3 cells per well. Each day, one plate was stained with crystal violet fixative solution for 30 min, rinsed in distilled water, and allowed to air dry. At the end of the experiment, crystal violet was dissolved by adding 100 μl of 50% ethanol containing 0.1 M sodium citrate to each well, and the absorbance was quantified at a 540 nm wavelength on a plate reader. Each experiment was repeated three times.
Radiography
Animals were X-rayed against the detector, and exposed with an X-ray at 35 kVp for 5 s by using a Faxitron Digital Radiographic Inspection unit (Faxitron, Tucson, AZ, USA) as previously described [54] . Osteolytic lesions were identified on radiographs as demarcated radiolucent lesions in the bone and quantified blindly by using ImageJ (NIH).
Wound-healing assays
DU145 B1/EV and DU145 B1/EGR1shRNA11 cells were seeded at a density of 5 × 10 6 cells in the 10-cm dish to attain hyperconfluency after 24 h. The media was changed the following day and the hyperconfluent 10-cm dish was scratched with a silicon-coated 1-ml pipette tip. A timed series of phase contrast pictures were taken at day 0, 1, and 2 using a AxioObserver Z1 Fluorescent Microscope (Zeiss). Plates were marked so that pictures were taken at precisely consistent positions along each individual scratch. Wound healing assays were quantified as described previously [55] . Each experiment was repeated three times.
Osteoclastogenesis assay
RAW264.7 cells were provided by Dr. Yibin Kang from Princeton University. RAW264.7 cells were seeded in triplicate at a density of 1.25 × 10 4 /cm 2 in a 12-well dish. After 24 h, cell cultures were supplemented with RANKL (20 ng/ml, R&D Systems, Minneapolis, MN, USA) for 2 days (priming) followed by application of 10% CM from DU145 B1/EV or either of DU145 B1/EGR1shRNA cell lines for an additional 2 days. Cells were fixed with 4% paraformaldehyde and TRAP stained as previously described [18] . Images were recorded randomly using a AxioObserver Z1 Fluorescent Microscope (Zeiss, Oberkochen, Germany) and quantified blindly. Osteoclasts were identified as TRAP-positive cells with three or more nuclei. Each experiment was repeated twice.
Statistical methods
GraphPad Prism 7 was used for graphs and statistics. Data were expressed as mean ± SEM or box-and-whisker plots. All data were analyzed using the two-tailed Student t test for comparison of two groups or one-way ANOVA for three groups or more. The Pearson test was used to assess the correlation study. Log-rank test (Wilcox survival) was used to analyze survival data. Differences were considered statistically significant when the P-value was <0.05.
